Journal of Parasitic Diseases: Diagnosis and Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Rapid Communication - Journal of Parasitic Diseases: Diagnosis and Therapy (2025) Volume 10, Issue 1

The Rising Challenge of Parasite Drug Resistance: A Global Health Perspective

James O. Smith*

Department of Pathology, University of Cambridge, United Kingdom

Corresponding Author:
James O. Smith
Department of Pathology
University of Cambridge,
United Kingdom
E-mail: james.smith@cam.ac.uk

Received: 25-Dec-2024, Manuscript No. AAPDDT-25-166320; Editor assigned: 28-Dec-2024, AAPDDT-25-166320 (PQ); Reviewed: 11-Jan-2025, QC No. AAPDDT-25-166320; Revised: 16-Jan-2025, Manuscript No. AAPDDT-25-166320 (R); Published: 22-Jan-2025, DOI:10.35841/2591-7846.10.1.209

Citation: Smith J O. The Rising Challenge of Parasite Drug Resistance: A Global Health Perspective, J Parasit Dis Diagn Ther. 2025; 10(1):209.

Introduction

Parasitic diseases continue to impose a substantial burden on global health, particularly in tropical and subtropical regions. Diseases such as malaria, leishmaniasis, schistosomiasis, and filariasis affect hundreds of millions of people annually, causing significant morbidity and mortality. While pharmacological interventions have long been the cornerstone of parasitic disease control, the emergence and spread of drug-resistant parasites are threatening these gains. Parasite drug resistance is not merely a clinical concern—it is a public health emergency that requires urgent and coordinated action [1, 2, 3, 4].

Understanding Parasite Drug Resistance

Drug resistance in parasites occurs when a parasite evolves to survive exposure to a drug that would normally kill it or inhibit its growth [5, 6, 7]. This resistance is often driven by genetic mutations, selective pressure from widespread and sometimes inappropriate drug use, and transmission dynamics that allow resistant strains to proliferate.

In protozoan parasites such as Plasmodium falciparum, resistance to antimalarial drugs like chloroquine, sulfadoxine-pyrimethamine, and even artemisinin has been documented. Similarly, in helminths, resistance to anthelmintics like albendazole and ivermectin is increasingly reported, especially in veterinary contexts but with growing concern for human populations.

Mechanisms and Spread

The mechanisms of resistance vary widely. In malaria, mutations in specific genes such as pfcrt and kelch13 are associated with resistance. In helminths, β-tubulin gene mutations have been linked to benzimidazole resistance. The spread of resistance is exacerbated by several factors:

  • Overuse and misuse of antiphrastic drugs.
  • Lack of diagnostic tools, leading to presumptive treatment.
  • Inadequate health infrastructure in endemic regions.
  • Incomplete treatment regimens due to poor access or patient non-adherence.

Implications for Public Health

The rise of drug-resistant parasites has profound implications. Treatment failures can lead to prolonged illness, increased transmission, and higher mortality. Drug resistance also drives up healthcare costs due to the need for more expensive second-line treatments and extended hospital stays. Moreover, it jeopardizes global efforts to control or eliminate parasitic diseases, as seen in the stalling progress against malaria in some regions [8, 9, 10].

Conclusion

Parasite drug resistance is an evolving challenge that threatens decades of progress in controlling parasitic diseases. It calls for an urgent reassessment of current treatment strategies and investment in sustainable public health interventions. As we navigate this era of resistance, innovation, surveillance, and collaboration will be key to safeguarding human health against these persistent threats.

References

  1. Wong F, de la Fuente-Nunez C, Collins JJ. Leveraging artificial intelligence in the fight against infectious diseases.Science.2023;381(6654):164-70.

    2. Indexed at, Google Scholar, Cross Ref

  2. Nii-Trebi NI. Emerging and neglected infectious diseases: insights, advances, and challenges. Biomed Res Int. 2017;2017(1):5245021.

    3. Indexed at, Google Scholar, Cross Ref

  3. Hao R, Liu Y, Shen W, et al. Surveillance of emerging infectious diseases for biosecurity. Sci China Life Sci.2022;65(8):1504-16.

    4. Indexed at, Google Scholar, Cross Ref

  4. Le T, Sun C, Chang J, et al. mRNA vaccine development for emerging animal and zoonotic diseases. Viruses.2022;14(2):401.

    5. Indexed at, Google Scholar, Cross Ref

  5. Li H, Bai R, Zhao Z, et al. Application of droplet digital PCR to detect the pathogens of infectious diseases. Biosci Rep.2018;38(6):BSR20181170.

    6. Indexed at, Google Scholar, Cross Ref

  6. Liu CL, Zhou T, Cheng LB, et al. The History of Controlling and Treating Infectious Diseases in Ancient China.Curr Med Sci.2024;44(1):64-70.

    7. Indexed at, Google Scholar, Cross Ref

  7. Wang X, Chakraborty B. The sequential multiple assignment randomized trial for controlling infectious diseases: a review of recent developments. Am J Public Health. 2023;113(1):49-59.

    8. Indexed at, Google Scholar, Cross Ref

  8. Morens DM, Fauci AS. Emerging pandemic diseases: how we got to COVID-19. Cell. 2020;182(5):1077-92.

    9. Indexed at, Google Scholar, Cross Ref

  9. Ellwanger JH, de Lima Kaminski V, Chies JA. Emerging infectious disease prevention: Where should we invest our resources and efforts?. J Infect Public Health. 2019;12(3):313-6.

    10. Indexed at, Google Scholar, Cross Ref

  10. Mercer A. Protection against severe infectious disease in the past. Pathog Glob Health. 2021;115(3):151-67.

    11. Indexed at, Google Scholar, Cross Ref

Get the App